Nextcure appoints dr. rakesh dixit to scientific advisory board

Beltsville, md., april 04, 2024 (globe newswire) -- nextcure, inc. (nasdaq: nxtc), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, today announced the appointment of rakesh dixit, phd, to its scientific advisory board. as an accomplished product developer whose expertise is focused on antibody-drug conjugates (adcs), dr. dixit will support nextcure in its efforts to build and develop its proprietary adcs, including lncb74 directed to b7-h4.
NXTC Ratings Summary
NXTC Quant Ranking